NCT05225558View on ClinicalTrials.gov

A Phase 2a Study, Effect of Vancomycin With vs Without Delpazolid (LCB01-0371) in Patients With MRSA Bacteremia

PHASE2TerminatedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 26, 2022

Primary Completion Date

February 21, 2024

Study Completion Date

March 18, 2024

Conditions
MRSA Bacteremia
Interventions
DRUG

Delpazolid

BID, PO

DRUG

Vancomycin

IV infusion per 2020 IDSA guideline

DRUG

Placebo of Delpazolid

BID, PO

Trial Locations (6)

13620

Seoul National University Bundang Hospital, Gyeonggi-do

15355

Korea University Ansan Hospital, Gyeonggi-do

61453

Chosun University Hospital, Gwangju

61469

Chonnam National University Hospital, Gwangju

03722

Severance Hospital, Seoul

05505

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

LigaChem Biosciences, Inc.

INDUSTRY

NCT05225558 - A Phase 2a Study, Effect of Vancomycin With vs Without Delpazolid (LCB01-0371) in Patients With MRSA Bacteremia | Biotech Hunter | Biotech Hunter